We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety Assessment of Intravitreal Mesenchymal Stem Cells for Acute Non Arteritic Anterior Ischemic Optic Neuropathy

This study is not yet open for participant recruitment.
Verified October 2017 by Instituto Universitario de Oftalmobiología Aplicada
Sponsor:
ClinicalTrials.gov Identifier:
NCT03173638
First Posted: June 2, 2017
Last Update Posted: October 3, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Collaborator:
University of Valladolid
Information provided by (Responsible Party):
Instituto Universitario de Oftalmobiología Aplicada
  Purpose

In this study the investigators propose to perform a Phase II Clinical Trial which seeks to evaluate the safety of cell therapy as a new treatment for patients who suffer from acute non-arteritic anterior ischemic optic neuropathy (NAION). If it is successful, a later study to assess efficacy will be performed.

This disease has an age-adjusted incidence rate of 10/100.000, and in many cases it results in blindness. Currently, there is no available treatment and second eye involvement occurs in approximately 15-25% of the cases.

All this background originates a particularly dramatic outcome for the patient. Therefore, it seems justified to evaluate new therapies that maintain or improve the visual function in these patients.

The Project includes a clinical trial whose purpose is the assessment of the safety of intravitreal administration of allogenic mesenchymal stem cells (MSC) in patients with NAION, a product in clinical research phase (PEI No. 15-007) already approved for other human clinical applications (PEI No. 15-007).

It can be considered that the therapy with intravitreal injection of MSC is a treatment option in patients with acute NAION, since through the paracrine properties of these cells (secretion of neurotrophic, immunomodulatory and anti-apoptotic factors) it may prevent or reduce the progression of axonal degeneration caused by this disease.


Condition Intervention Phase
Non Arteritic Ischemic Optic Neuropathy Procedure: intravitreal injection of MSV Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Safety Assessment of Intravitreal Injection of Mesenchymal Stem Cells for Acute Non Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Resource links provided by NLM:


Further study details as provided by Instituto Universitario de Oftalmobiología Aplicada:

Primary Outcome Measures:
  • Absence of inflammatory reaction - Slit lamp exploration - SUN (Standardization of Uveitis Nomenclature) scale [ Time Frame: Changes compared to baseline in visits V1 (1day), V2 (1week), V3 (1 month), V4 (3 months), V5 (6 months) and V6 (12months) and in any unscheduled visit any patient might need ]
    Following the SUN scale, the parameters that will be taken into account in the slit lamp exploration will be: cells and flare in anterior chamber, and vitreous flare


Secondary Outcome Measures:
  • Adverse events procedure-related (intravitreal injection) [ Time Frame: Throughout the study after treatment in visits V1 (1day), V2 (1week), V3 (1 month), V4 (3 months), V5 (6 months) and V6 (12months) and in any unscheduled visit any patient might need ]
    Conjunctival haemorrhages, anterior chamber inflammation, changes in intraocular pressure, infectious endophthalmitis, vitreous inflammation, retinal detachment, choroidal detachment, corneal opacities, lens opacities, neovascularization, macular edema or any other adverse event that may appear


Estimated Enrollment: 5
Anticipated Study Start Date: November 2017
Estimated Study Completion Date: July 2019
Estimated Primary Completion Date: April 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Mesenchymal stem from valladolid (MSV)
Allogenic mesenchymal stem cells from bone marrow
Procedure: intravitreal injection of MSV
A unique intravitreal injection of MSV in acute fase of NAION

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with acute unilateral NAION (within two weeks after the first symptoms) with at least two of the following:

    1. Sudden and unpainful monocular vision loss
    2. Visual field defects
    3. Dyschromatopsia.
    4. Ocular nerve head edema.
    5. Afferent relative pupil defect.
  • Patients ≥ 50 years old, able to freely give informed consent.
  • Best corrected visual acuity (BCVA) ≤ 0,1 in study eye.
  • Pseudophakia in study eye.
  • Preserved pupil sphincter muscle motility
  • Signed informed consent form before any study procedure.
  • Signed data protection consent form before any study procedure.

Exclusion Criteria:

  • Giant cell arteritis evidence (clinical history, Erythrocyte sedimentation rate (ESR), C-Reactive Protein)
  • Evidence of any other etiology that may justify the optic neuropathy (even in the non-study eye)
  • History of systemic vasculitis, multiple sclerosis, collagenopathies or previous cancer treatments.
  • Hypersensitivity or allergy to any compound used in the study, including investigational medicinal product (IMP).
  • Positive pregnancy test at baseline
  • Participation in any other research study within 2 months

Ophthalmic exclusion criteria

  • History of uveitis or active ocular inflammation
  • History or evidence of glaucoma or high intraocular pressure ( ≥ 24 mmHg in either eye).
  • Mean opacities or retinal pathologies in the study eye.
  • Any previous vitreous or glaucoma surgery in the study eye
  • Cataract surgery within 3 months in the study eye
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03173638


Contacts
Contact: Sonia Labrador, MD 0034 654936019 slabradorv@ioba.med.uva.es
Contact: Francisco Blazquez, MD 0034 983184734 blazquez@ioba.med.uva.es

Sponsors and Collaborators
Instituto Universitario de Oftalmobiología Aplicada
University of Valladolid
Investigators
Principal Investigator: José C Pastor Jimeno, MD, PhD IOBA-UVA
  More Information

Additional Information:
Responsible Party: Instituto Universitario de Oftalmobiología Aplicada
ClinicalTrials.gov Identifier: NCT03173638     History of Changes
Other Study ID Numbers: IOBA01-2016
2016-003029-40 ( EudraCT Number )
First Submitted: May 24, 2017
First Posted: June 2, 2017
Last Update Posted: October 3, 2017
Last Verified: October 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Instituto Universitario de Oftalmobiología Aplicada:
acute non arteritic anterior ischemic optic neuropathy
mesenchymal stem cells
intravitreal injection
safety

Additional relevant MeSH terms:
Ischemia
Peripheral Nervous System Diseases
Optic Nerve Diseases
Optic Neuropathy, Ischemic
Pathologic Processes
Neuromuscular Diseases
Nervous System Diseases
Cranial Nerve Diseases
Eye Diseases
Vascular Diseases
Cardiovascular Diseases